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A combined computational-
experimental approach to define 
the structural origin of antibody 
recognition of sialyl-Tn, a tumor-
associated carbohydrate antigen
Ron Amon1, Oliver C. Grant2, Shani Leviatan Ben-Arye1, Spandana Makeneni2, 
Anita K. Nivedha2, Tal Marshanski1, Christoffer Norn3, Hai Yu4, John N. Glushka2, 
Sarel J. Fleishman3, Xi Chen4, Robert J. Woods2 & Vered Padler-Karavani1
Anti-carbohydrate monoclonal antibodies (mAbs) hold great promise as cancer therapeutics and 
diagnostics. However, their specificity can be mixed, and detailed characterization is problematic, 
because antibody-glycan complexes are challenging to crystallize. Here, we developed a generalizable 
approach employing high-throughput techniques for characterizing the structure and specificity of such 
mAbs, and applied it to the mAb TKH2 developed against the tumor-associated carbohydrate antigen 
sialyl-Tn (STn). The mAb specificity was defined by apparent KD values determined by quantitative 
glycan microarray screening. Key residues in the antibody combining site were identified by site-
directed mutagenesis, and the glycan-antigen contact surface was defined using saturation transfer 
difference NMR (STD-NMR). These features were then employed as metrics for selecting the optimal 
3D-model of the antibody-glycan complex, out of thousands plausible options generated by automated 
docking and molecular dynamics simulation. STn-specificity was further validated by computationally 
screening of the selected antibody 3D-model against the human sialyl-Tn-glycome. This computational-
experimental approach would allow rational design of potent antibodies targeting carbohydrates.
Carbohydrates (glycans), as well as glycoproteins and glycolipids, are major cell surface components, and many 
monoclonal antibodies (mAbs) have been developed to target these molecules for various applications1. Changes 
in cellular glycosylation are common in cancer due to aberrant expression of glycosyltransferases, glycosidases, 
and transporters, as well as differences in the abundancy of carbohydrate building blocks2–4. Such alterations 
can result in unique antigenic glycans referred as Tumor-Associated Carbohydrate Antigens (TACAs). TACAs 
are used clinically as disease markers, for example, sialyl Lewis a (sLea) is used for staging of pancreatic cancer5. 
Additionally, targeting TACA epitopes has become significant for managing various human cancers6,7. An anti-
body against the ganglioside GD2 has shown beneficial effects in neuroblastoma treatment8 and several other 
anti-carbohydrate antibodies are currently in clinical trials1. Although mAbs are clinically important tools, anti-
bodies against carbohydrates tend to have low affinity9 and complex or mixed specificity10. In addition, the rec-
ognition of the glycan antigen can depend on glycan density, valency, presentation, and flexibility11. The paucity 
of high affinity and/or high specificity antibodies against carbohydrate targets is a crucial limitation in exploiting 
glycans as disease markers or therapeutic targets12.
The disaccharide Neu5Acα2–6GalNAcα1-O-Ser/Thr is a common short O-glycan TACA conjugated to pro-
teins, also referred to as sialyl-Tn (STn; AcSTn). While this is a rare antigen or occluded in normal tissues due to 
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further O-acetylation of the sialic acid (Sia)3, it is present in more than 80% of human carcinomas13, including 
those of the pancreas, breast, prostate, ovaries and colorectum14,15. Cells expressing the STn antigen have reduced 
adherence to extracellular matrix components, and show higher migration rates, thus promoting metastasis16. 
Moreover, the presence of STn is associated with decreased overall survival, and therefore has been the target for 
various immunotherapeutic research efforts13. There have been several unsuccessful attempts to develop a clin-
ical viable vaccine against this antigen, including Theratope for human breast cancer patients that had induced 
STn-specific IgGs. Phase-III vaccine trial was carried out but largely failed because the participants had not been 
pre-evaluated for expression of STn13. In the Database of Anti-Glycan Reagents (DAGR; https://ccr2.cancer.
gov/resources/Cbl/Tools/Antibody/), 14 different mAbs targeting STn are listed, albeit generally of low spec-
ificity. Some of these antibodies bind STn with either terminal N-acetylneuraminic acid (AcSTn; Neu5Acα2–
6GalNAcαR) or N-glycolylneuraminic acid (GcSTn; Neu5Gcα2–6GalNAcαR), while another antibody did not 
bind any of these antigens on a glycan microarray15. Thus, improving the specificity of anti-STn antibodies is 
key for their potential use as tumor therapeutic and diagnostic (theranostics). Rational design can be used to 
improve an existing mAb, and for that purpose it is first imperative to define the structural features of the mAb 
binding region by co-crystallizing the antibody binding fragment (Fab) with the glycan antigen. Co-crystals of 
antibodies complexed with the corresponded TACA were generated for Lex, Ley and Tn antigens9. Yet obtain-
ing such Fab-antigen complex co-crystals is not always straightforward, and even more challenging in the case 
of anti-carbohydrate antibodies, due to their general low affinity9 and the plasticity of glycans. An alternative 
approach is to use computational modeling of the antibody, the glycan epitope, and their antibody-glycan binding 
interactions. However, computational approaches often lead to multiple plausible models, and orthogonal experi-
mental data is essential for selecting the most likely model.
The relatively conserved structure of antibody domains, combined with the limited number of canonical 3D 
structures of the mAb hypervariable loops in the complementary determining regions (CDRs) makes it pos-
sible to predict the 3D structure of an antibody with reasonable accuracy17–19. Models of the antibody Fab can 
then be employed for automated ligand docking, using either experimental or theoretical structures of the gly-
cans20. During docking, the small molecule ligand is generally permitted to be flexible while the protein receptor 
is often kept rigid, although a subset of protein side chains may be allowed flexibility. The accuracy of glycan 
docking can be enhanced if their unique conformational preferences are considered in the docking protocol21. 
Nevertheless, the accuracy (both in terms of the 3D pose of the ligand in the binding site, and its theoretical 
interaction energy) of computational docking alone is highly variable, and ideally the selection of the optimal 
theoretical antigen-antibody docking pose should be reinforced by experimental data22.
TKH2 is a unique anti-STn mAb, generated by immunization of mice with ovine submaxillary mucins23. This 
antibody binds various human cancer cells, such as lung, colon, breast, stomach and pancreas23. Unlike several 
other anti-STn antibodies15, the specificity of TKH2 antibody has been examined only against a limited set of gly-
cans23 but not by more systematic glycan microarray assays. Here we developed an experimental-computational 
approach to investigate the specificity of anti-carbohydrate antibodies using the TKH2 as a model system. First, 
we obtained the antibody sequence by molecular cloning, and used it for antibody homology modelling and 
Molecular Dynamics (MD) simulations followed by computational docking of the glycan antigen. Subsequently, 
we investigated the antibody specificity by a sialoglycan microarray and alanine mutagenesis scanning, then 
together with STD-NMR defined the practical optimal antibody-antigen interactions. Computational grafting 
of 86 STn-related carbohydrate antigens of the human glycome database on the validated 3D antibody model 
further demonstrated the high specificity of the TKH2 antibody to the STn target. This approach can be used to 
explicitly elucidate antibody-antigen interactions that can be further used to improve the specificity of existing 
anti-carbohydrates antibodies to ultimately increase the use of such antibodies as theranostic tools.
Results
Obtaining VH and VL sequences of TKH2, an anti-STn monoclonal antibody. The anti-STn mAb 
TKH223 holds great promise as a cancer theranostic tool (e.g. for therapy, diagnosis and monitoring of sTn-pos-
itive lesions) and was therefore selected for in-depth analysis to decipher its interaction with STn, and to deter-
mine its specificity using both various computational and experimental tools. To establish a computational model 
of the antibody, we determined the amino acid sequences of the mAb’s heavy and light chains variable domains 
(VH and VL; Supplementary Fig. 1a), which were then cloned and expressed with a human IgG Fc for further 
examination (Supplementary Fig. 1b).
For this purpose, we obtained the BM-4 hybridoma (ATCC), total RNA was extracted followed by cDNA syn-
thesis and subsequently VH and VL fragments were amplified from the cDNA in a first-round PCR using appro-
priate primers (Supplementary Fig. 1b). For VH amplification, we used primers for mouse IgG1 since TKH2 was 
reported to be an IgG123. For the kappa chain, the PCR amplification resulted in three similar-sized products and 
one larger product (data not shown), while no products were amplified in lambda VL PCR. Subsequently, the 
first-round PCR products were purified and sequenced (Supplementary Table 1a).
To confirm the identity of the obtained sequences, we used IgBLAST (http://www.ncbi.nlm.nih.gov/igblast/) 
against mouse Ig germline sequence database that also provides the translated sequence within the context of an 
antibody (Supplementary Table 1b,c), either according to the IMGT numbering system (http://www.imgt.org/) 
or KABAT numbering system (http://www.bioinf.org.uk/abs/). IgBLAST analysis of the heavy chain VH sequence 
aligned it to the IGHV2-3*01 mouse Ig germline gene sequence from the IMGT database. Thus, VH allele is 
closely related to family #2 and the germline gene to 3*01. The alignment also revealed several mutations in the 
query sequence compared to the germline sequence, including in the CDR regions, suggesting affinity maturation 
of the antibody. We then sequenced three of the PCR amplified light chain VL fragments and compared them 
by multiple sequence alignment (MSA) using ClustalW2 (http://www.ebi.ac.uk/Tools/msa/clustalw2) reveal-
ing two light chain variants. Since the hybridoma is in fact a fusion of two cells: the antibody secreting B cell 
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and the immortalized myeloma, these two variants likely represented each one of them. In this specific hybri-
doma, the antibody-secreting B cell was fused to an SP2/0 myeloma cell23 that is known to express an aberrant 
non-functional kappa light chain24,25. Comparing the SP2/0 sequence (GenBank: M35669.1) with the obtained 
sequences by MSA revealed that two of them indeed represented the myeloma, while the third sequence likely 
represented the antibody VL (Supplementary Table 1a).
IgBLAST tool was used to align this sequence to mouse Ig germline, and the amino acid sequence of the VL 
(Supplementary Table 1b) was obtained. VL seemed to belong to the IGKV4-59*01 family and mutations were 
also observed compared to the germline sequence. The VH fragment was further amplified in a second-round 
nested PCR and these products were amplified again in a third nested PCR. Similarly, the VL fragment was 
amplified in second nested PCRs. Final products of VH and VL nested PCR rounds introduced restriction sites 
in both termini of the variable sequences, to facilitate cloning of the variable segments into expression vectors 
(Supplementary Fig. 1b). The PCR products were purified from gel, and sequence analysis validated that no muta-
tion in the VH/ VL sequences were caused by PCR processes.
Antibody modeling and molecular dynamics simulations. To generate a 3D structure for the 
immune complex of STn bound to the antibody, we used the VH/VL sequences to create a homology model 
for the antibody variable fragment (Fv), then refined the 3D structure by subjecting it to molecular dynamics 
simulations. Two homology models were built using PIGS server (http://circe.med.uniroma1.it/pigs), this tool is 
fast and available online. Three additional models were obtained using the recently developed knowledge-based 
AbPredict algorithm. AbPredict tool combines segments from various antibodies, then samples large conforma-
tions space resulting with the low energy homology models26.
The fold of the protein backbone was very similar between the PIGS and AbDesign models (Cα Root Mean 
Square Deviation, RMSD, of 1.57 Å), however the sidechains differed more significantly (RMSD 2.35 Å) (Fig. 1a). 
We selected one model from each program for further analysis. PDB template entries sequences that were used 
to build the PIGS homology model had 89.9% (VL) and 82.46% (VH) identity to the TKH2 sequences, while in 
AbPredict model the identity to the TKH2 sequences were 91.9% for VL, 58.8% for L3, 86.0% for VH and 66.7% 
for H3. Both homology models were subjected to a 500 ns MD simulation in explicit water. An RMSD relative 
to the initial homology model showed that the model generated by PIGS was stable throughout the production 
simulation, whereas the Cα atom positions of the model from AbPredict were initially relatively more volatile, but 
stabilized after 30 ns of simulation (Fig. 1b). An RMSF (Root Mean Square Fluctuation) of the protein Cα atoms 
(Fig. 1c) revealed a similarity in the per-residue flexibility between both structures. The AbPredict model had 
Figure 1. Structural modeling of TKH2 monoclonal antibody. (a) Structure-based alignment of TKH2 mAb 
models with the heavy and light chains of PIGS model shown in red and blue respectively, and the AbPredict 
model shown in grey. The leftmost alignment is of the heavy chain (111 atom pairs, 0.8 Å RMSD), and the 
rightmost alignment is with the light chain (103 atom pairs, 0.7 Å RMSD). The overall RMSD of 1.57 Å indicates 
a difference in the heavy and light chain relative position between the two models. (b) An RMSD plot of both 
structure models Cα atoms relative to their initial structures over the 500 ns MD simulation. (c) Average atomic 
fluctuations of Cα atoms over the 500 ns simulations of PIGS and AbPredict structure models without the 
ligand. Residues that were selected to be flexible during one of the docking protocols are labelled (VH−Y32, 
VH−R96, VH−F97 and VL−W91).
www.nature.com/scientificreports/
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higher average values in general due to the higher degree of mobility in the initial 30 ns of simulation (Fig. 1c), 
but overall both structures displayed a marked similarity in per-residue mobility. The degree of fluctuation was 
comparable to that observed during an MD simulation of a mAb crystal structure (data not shown).
Computational docking and assessment of pose stability. We next generated a preliminary 3D 
model for the STn glycan ligand and used computational docking to generate putative poses of the STn ligand in 
the TKH2 combining site and subsequently performed molecular dynamics simulations to assess pose stability. 
3D structures for the six known rotamers of Neu5Acα2–6GalNAcαOMe were generated using the GLYCAM-Web 
(www.glycam.org/cb)27 server that generates 3D models of carbohydrates based on the GLYCAM06 forcefield28. 
In the first protocol, each rotamer was rigidly docked to 25 snapshots from the MD simulation. The sidechains 
of four amino acids residues within the CDRs (VH−Y32, VH−R96, VH−F97 and VL−W91), that showed sig-
nificant motion during the unliganded MD simulations (Fig. 1), were allowed to be flexible during the ligand 
docking. Twenty poses were generated for each docking run, resulting in 3,000 poses (=6 rotamers × 25 snap-
shots × 20 poses) for each model (PIGS and AbPredict). Out of the 6,000 screened poses, the resulting poses for 
each rotamer were clustered amongst themselves using a 2 Å cut-off (see Methods section for details) to remove 
similar poses. The top scoring pose from the top 20 clusters from each of the 6 rotamers (120 structures per 
homology model) were selected for MD simulation.
In a second protocol, the lowest energy rotamer of the glycan was flexibly docked to 150 snapshots from the 
MD simulation of the antibody model, generating additional 3,000 poses (20 poses retained from docking to 150 
snapshots) for each homology model. Thus, a total of additional 6,000 poses were screened. After clustering, the 
50 top scoring poses of each homology model were selected for MD simulation.
In total, we screened 12,000 plausible models that were then narrowed down to 340 putative structures (120 
from rigid protocol and 50 from flexible protocol for each homology model). These were then subjected to a 
100 ns MD simulation to assess their stability in the antibody binding site. An RMSF analysis was performed on 
the last 10 ns of the simulation for each ligand. Poses that had a high degree of instability in the last 10 ns were 
filtered out (Fig. 2b), removing 260 poses while retaining 80 putative poses for further analysis.
Experimental antibody specificity and glycan array alanine scanning. To further discriminate 
between models, and to assess the binding mechanism and specificity, the original mouse TKH2 antibody 
(mTKH2) and the human IgG Fc chimeric antibody (hTKH2) were purified from BM-4 and transfected 293A 
cells, respectively (Supplementary Fig. 1a–c). Antibody specificity was determined by screening the mAbs against 
a sialoglycan microarray29,30 (Fig. 3a; Supplementary Fig. 1d). Apparent binding curves were generated by titrat-
ing the antibody at multiple concentrations (16 serial dilutions, 400–0.00256 nM), and apparent KD values derived 
by fitting an equilibrium binding model to the data (Fig. 3b). The measurement of apparent KD values provides an 
important quantification of relative affinities31, which may otherwise only be qualitatively inferred from microar-
ray data. The top binders were STn containing a terminal Neu5Ac (AcSTn; glycan #5; Neu5Acα2–6GalNAcα) or 
its 9-O-acetylated analog (glycan #23; 9Ac-AcSTn; 9-O-Ac-Neu5Acα2–6 GalNAcα). Also recognized were gly-
cans #27 and #31 (Neu5Acα2–6Galβ and 9-O-Ac-Neu5Acα2–6 Galβ, respectively), which were similar to glycans 
#5 and #23, but differ by having a C2-hydroxyl group instead of an acetamido group in the penultimate sugar and 
a β-glycosyl linkage to the aglycon linker. Unlike other anti-STn antibodies15, TKH2 has a pronounced prefer-
ence for AcSTn over GcSTn (STn with a terminal Neu5Gc), as demonstrated by the much lower affinity against 
glycans #6 (Neu5Gcα2–6GalNAcα) and #24 (9-O-Ac-Neu5Gcα2–6GalNAcα; 9Ac–GcSTn) (Fig. 3a,b). Figure 3c 
demonstrates the recognition of glycans #23 and #24 using a 3D structure with 9Ac–GcSTn. Galβ residue, found 
in glycan #27 and #31 is more relevant to N-glycosylation, that are not supposed to be recognized by TKH2, which 
was generated against the O-glycan target STn. It is possible that the high affinity together with the ligand high 
Figure 2. Pose filtering with RMSD/RMSF. (a) An example of a discarded pose (grey) that was repositioning 
in the binding site, and thus showed a high and variable RMSD, as well as a selected, stable pose (green). (b) 
All poses ordered by average RMSF during the last 10 ns of MD. Only poses that displayed a stable RMSD and 
therefore low RMSF for the last 10 ns of the simulation were selected. Poses that were not bound tightly by the 
protein (RMSF higher than 1.0 Å) were discarded.
www.nature.com/scientificreports/
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density on the glycan microarray led to this detection29. No binding was detected to any Neu5Acα2–3-containing 
glycan structures.
Based on antibody structure models and CDR identification, 18 residues were selected for alanine scanning 
to determine their relative contribution to binding (16 residues within CDR regions). These mutated human-IgG 
chimeric antibodies were purified and their binding preferences were analyzed by the glycan microarray. Each 
purified antibody was applied at 16 different concentrations to generate a binding curve and calculate the appar-
ent KD against each glycan on the array (Supplementary Fig. 2). To evaluate the effect of each mutation on reac-
tivity of the antibodies, the apparent KD values for the mutants were converted to free energies and reported as 
the change in free energy (ΔΔG) relative to the wild-type antibody (Fig. 4). This analysis revealed that some 
mutations, such as VH–S31A and VL–S92A made only minor influences on the apparent KD (ΔΔG close to 0) 
while others, such as VL–W91A and VH–G33A impaired the binding against all glycans, but to a greater extent 
for the glycans containing GalNAc instead of Gal (glycan #5 versus glycan #27; glycan #23 versus glycan #31). 
The latter observation suggests that these residues interact with the acetamido group of the GalNAc. The impact 
of some mutations, such as VH–W52A and VL–Q89A were so dramatic that it was not possible to calculate the 
apparent KD for any glycan, suggesting they played key roles in forming binding site structure or affinity interac-
tions with the ligand.
Pose filtering with glycan STD-NMR and antibody alanine scanning. Saturation transfer difference 
NMR experiments determine the difference in nuclear Overhauser enhancement (nOe) magnetization transfer 
from the irradiated protein to a bound ligand then subsequently to a released ligand32. The relative increase in 
a ligand proton signal is proportional to its proximity to protons in the protein. Such data can provide valuable 
information related to the relative orientation of the bound glycan within the mAb combining site33–35. It is pos-
sible to compare the experimental STD enhancements with those computed for a docked pose, and filter out 
any poses whose theoretical STD enhancements are not in agreement with the experimental values36 (Table 1). 
The STD-NMR measurements mapped onto a 3D structure of the antigen Neu5Acα2–6GalNAcαOMe and the 
agreement between the predicted and experimental STDs is shown in Fig. 5a. Both the STD-NMR data and the 
theoretical structure (Fig. 5a,b; Supplementary Fig. 3; Supplementary Table 2) suggest a key role for the acetamido 
Figure 3. TKH2 glycan microarray analysis of specificity and affinity. (a) Binding of mTKH2 to diverse glycans 
was examined at 30, 12, 6 and 2.4 ng/µl by a sialoglycan microarray printed at four replicate spots per glycan. 
Relative fluorescence units (RFU) was calculated as percentage of maximal binding at each concentration, 
followed by averaging the relative RFU rank of the four tested antibody concentrations for each glycan 
(mean ± SEM; 9Ac denotes 9-O-acetylation on the sialic acids). Representative of two independent experiments 
(full data in supplementary Excel file). (b) Binding of the chimeric hTKH2 was tested at 16 serial dilutions (400–
0.00256 nM) for the top six bound glycans (full data in supplementary Excel file). Apparent KD was calculated 
according to non-linear fit with one-site specific binding using GraphPad Prism 6.0. (c) Modeling of the STn 
ligand within the antibody binding site. The N-glycolyl (5Gc; green) and 9-O-acetylation (9Ac; cyan) sialic acid 
derivatives were built onto the final 3D structure model of TKH2 (grey). Proximal amino acids in the antibody 
binding site are colored.
www.nature.com/scientificreports/
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moiety in the binding of the antigen to TKH2, with that of the Neu5Ac residue being the most significant. The 
pose that gave the best agreement with the STD-NMR data was the most stable in the binding site during the last 
10 ns of MD and resulted in a strong theoretical affinity. This pose, optimally selected out of the remaining 80 
putative poses, was further validated by the experimental alanine scanning, as it placed the antigen proximal to 
key antibody residues (e.g. VL–Q89 and VH–W52 whose mutation to alanine resulted in undetectable binding; 
Fig. 4). In the selected unique pose (Fig. 5c) the sialic acid residue is proximal to both VH–W52 and VH–Y32, 
although it is not forming direct interactions with VH–Y32. The interaction with VH–W52 would be through the 
methyl group of Neu5Ac. The glycerol arm of sialic acid is positioned to interact directly with both VL–L96 and 
VL–Q89. Given the importance of the methyl and glycerol shown in the STD-NMR results, the proximity analysis 
can explain why the mutagenesis of VH–W52 and VL–Q89 to alanine abolished the binding. The GalNAc ring 
forms a stacking interaction with VL–W91 that is characteristic of carbohydrate binding37. The reducing terminal 
of the GalNAc is positioned such that glycans with either α or β anomeric configurations would be physically 
tolerated in the combining site.
Glycan array screening data support antibody-ligand model. The data from glycan array screening 
provided further experimental evidence for the importance of the acetamido moiety on Neu5Ac within the STn 
ligand when bound by TKH2 (Fig. 3a,b). This analysis clearly showed the reduced binding when the terminal 
sialic acid was rather Neu5Gc instead of Neu5Ac (Figs 3a,b and 4; Glycan IDs #6 and 24). The N-glycolyl moi-
ety of Neu5Gc had a destabilizing effect perceived through reduced binding and a 1000-fold decreased affinity 
(Fig. 3b; Glycan IDs #5 and #6 are 0.13 nM to 132 nM, respectively, hence reduced affinity by at least 2 orders of 
magnitude). In contrast, the 9-O-acetylation sialic acid derivatives had a rather stabilizing effect (Figs 3a,b and 
4; Glycan IDs #23 and 27), and were affected similarly to the original STn antigen Glycan ID #5 by the alanine 
scanning (Fig. 4). While glycan arrays currently hold a limited set of glycans that can be synthesized or properly 
purified, recent advances provide computational exploration of the much greater glycome for a more complete 
view on expected antibody specificity. Based on an examination of the optimal pose of STn in the binding site, the 
lack of measurable affinity for glycans terminating in Neu5Acα2–3 Gal sequences appears to arise from a loss of 
favorable interactions, rather than from unfavorable steric interactions. A low energy shape (-gauche ϕ angle)38 of 
Figure 4. ΔΔG of apparent KD fold change of alanine-scanning mutants. Apparent KD [nM] of hTKH2 and 
related mutants were calculated as described in methods section. Then, the fold change for each glycan was 
calculated as apparent KD of mutant Ab divided by the apparent KD of the original Ab (relative apparent KD). 
The relative binding free energy (ΔΔG in kcal/mol) was then calculated [ΔΔG = RTln (apparent KD/reference 
apparent KD)]. ΔΔG serves to quantify the effect of the specific amino acid residue mutation to alanine on 
Ab reactivity: ΔΔG ≅ 0, ΔΔG > 0, ΔΔG < 0, respectively suggest that the mutation has minimal effect, 
destabilizing effect, or stabilizing effect on Ab binding (9Ac denotes 9-O-acetylation on the sialic acids).
Pose ID
Docking 
rescorea
STD-NMR 
Correlationa
RMSF 
(Å)a
AbPredict.F.115.6 −9.5 0.74 0.6
PIGS.F.107.2 −7.9 0.68 0.8
PIGS.F.65.5 −8.1 0.63 0.9
Table 1. Docking poses that pass the docking rescore, RMSF and comparison to STD-NMR values filtering 
steps. aAll calculations were performed on the last 10 ns of the MD simulation.
www.nature.com/scientificreports/
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the Neu5Acα2–3 Gal sequence could readily fit into the combining site when the Neu5Ac ring was superimposed 
onto that in the STn ligand (Supplementary Fig. 4). However, the Gal residue in the Neu5Acα2–3 Gal sequence 
was not located in the same position as in the STn ligand, and was unable to form the same stabilizing interactions 
with the antibody.
Computational carbohydrate grafting for predicting putative off-targets within the known 
human glycome. The Gly-Spec webtool39 available at www.glycam.org/gr was used to perform computa-
tional carbohydrate grafting40 on the validated 3D model of the glycan-mAb complex with the known human 
sialyl-Tn-glycome. The technique first searches for human glycans that contain the antigen as part of their struc-
ture and then builds the 3D structure of that human glycan into the mAb binding site by growing out the larger 
glycan from the antigen “core” and adjusting the glycosidic linkages within normal ranges to relieve any steric 
overlaps. Glycans that can fit in the binding site without significant steric overlaps are putative off-targets for the 
specific antibody, and information such as disease/healthy state and tissue location can be retrieved from www.
glycome-db.org using the glycan ID number. In the case of TKH2, 86 human glycans were found to contain the 
antigen within their structure, however none were predicted to be bound by TKH2. The orientation of the antigen 
in the TKH2 binding site occluded the glycerol arm of the sialic acid, as well as the O3 and O4 of the GalNAc 
(Fig. 5c). No larger glycans were found that displayed the antigen at the non-reducing terminal. Thus, the TKH2 
Ab was predicted to be highly specific for Neu5Acα2–6GalNAcα- within the human sialyl-Tn-glycome. The com-
putational carbohydrate grafting method is useful for predicting specificity for glycans that contain a high affinity 
binding determinant, however it does not directly address whether other binding determinants could bind with 
high affinity. Thus, the array data (Fig. 3a) was important to demonstrate that glycans with a Siaα2–3-linkage are 
generally excluded from TKH2 recognition. The repertoire of those experimentally recognized sialoglycans on 
the array further support the glycome-DB computational screening of the TKH2, demonstrating its high speci-
ficity for Neu5Acα2–6GalNAcα-R.
Figure 5. Experimental and computational cross validation of ligand-Ab complex. (a) Graphical representation 
of normalized STD-NMR for STn antigen in complex with TKH2. The experimental STD-NMR values mapped 
onto a 3D structure of the antigen (Neu5Acα2–6GalNAcα-R). The antigen is shown in white licorice, with 
signal intensity for the hydrogens shown on a color scale (increasing signal intensity from yellow to red to 
black; atoms with no signal are colored white). A 3D-SNFG icon36 in the center of the residue ring depicts the 
Neu5Ac (purple octahedron) and Gal (yellow cube) residue. The figure was generated using VMD 1.9.351. (b) 
TKH2 binding site with residues experimentally mutated to alanine (licorice with a transparent surface). The 
residues are colored (white to red with a 2.2 gamma correction) by the change in apparent KD values (array data) 
for Neu5Acα2–6GalNAcα-ProNH2 binding when that residue was mutated to an alanine. Mutation of residues 
VL–Q89A and VH–W52A (burgundy) resulted in undetectable binding. The 3D structure shown is the final 
structure from the 100 ns MD simulation of the selected pose. (c) The two branch points (light grey licorice) 
from Neu5Acα2–6GalNAcα (dark grey licorice) found within the known human glycome are exemplified 
by glycan 9187 (glycomeDB ID). A glycan with extensions at either the Neu5Ac O8 or the GalNAc O3 are 
not predicted to fit in the TKH2 combining site based on the generated complex model. Glycans containing 
Neu5Acα2–6GalNAcα with extensions at the O4 of either the Neu5Ac or GalNAc have not been observed in 
humans.
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Discussion
Important advances in antibody modelling and antigen docking have been made recently35. Yet the accuracy of 
computational docking alone is sensitive to a plethora of features and highly variable, thus the selection of the 
optimal theoretical antigen-antibody docking pose needs to be reinforced by experimental data22,41,42. Glycan 
microarray studies present the binding preferences of glycan-binding proteins with high resolution and can be 
used to guide MD simulation toward potent antibody-glycan interaction40. Modeling can further shed light on 
binding preferences determined in these arrays e.g. the effects of different linkers on binding43. Here we describe 
an experimental-computational approach to delineate the binding features of anti-carbohydrate antibodies, com-
bining glycan microarray, site-directed mutagenesis, STD-NMR, modeling, docking and MD simulations. This 
method allowed to select one antibody-antigen model out of 12,000 plausible poses. The selected pose could be 
tightly associated to both the theoretical and experimental data, thereby supporting the wider implementation 
and applicability of this method to circumvent challenging co-crystalizing efforts.
STn is a tumor-associated carbohydrate antigen and antibodies against it are potential cancer theranostics44, 
which prompted efforts to target it by therapeutic cancer vaccines13. Several monoclonal antibodies against STn15 
have been developed but none have been crystallized thus far. We show that the anti-STn TKH2 mAb is highly 
specific to a limited set of closely related glycans, and has exceptionally high affinity with apparent KD in the nM 
range, as opposed to other anti-carbohydrate antibodies9. We used experimental STD-NMR to define STn glycan 
regions that are proximal to the TKH2 mAb surface, and site-directed mutagenesis to identify key-residues in the 
CDRs that are critical for antigen binding33,40. Additional antigen-antibody complexes could then be generated 
for related glycan antigens, by grafting glycan sub-structural features onto the optimal pose obtained by ligand 
docking. Subsequently, computational grafting33,40 provided an additional mechanism for pose validation, by 
enabling a direct comparison of the theoretical specificities for a range of glycans against the specificities observed 
by glycan array screening. An ideal model should be consistent with the STD-NMR, site-directed mutagenesis 
data, and glycan array data. With such a validated model, it was then possible to interpret the observed specifici-
ties in terms of molecular structure, and to formulate hypotheses regarding potential untested cross-reactivities. 
The Gly-Spec Webtool (www.glycam.org/gr)39 was developed to facilitate such specificity prediction33. The com-
bined experimental and computational approach presented here provided a 3D structural basis for explaining 
the specificity of the anti-cancer mAb TKH2. The methods employed in this study are generally applicable to 
carbohydrate-mAb complexes, and therefore should be broadly useful for defining the structural origin of the 
specificity of anti-carbohydrate antibodies. Given the importance of carbohydrates as disease markers, and the 
challenges in characterizing carbohydrate-antibody complexes crystallographically, the ability to routinely gen-
erate experimentally-consistent 3D structures for carbohydrate-antibody complexes has the potential to signifi-
cantly advance the development of therapeutic and diagnostic antibodies.
Methods
Cell culture. The BM-4 mouse hybridoma cells expressing TKH2 antibodies were obtained from the 
American Type Culture collection (ATCC). For culturing BM-4, cells were grown in RPMI-1640 medium sup-
plemented with 10% heat inactivated fetal bovine serum (FBS), 2 mM L-glutamine, 100 units/ml penicillin and 
0.1 mg/ml streptomycin, all from biological industries. For antibody purification, BM-4 cells were grown in 
DCCM-1 (biological industries) medium supplemented with 2 mM L-glutamine, 100 units/ml penicillin and 
0.1 mg/ml streptomycin. The 293A human embryonic kidney cells were obtained from Life technologies. 293A 
cells were grown in DMEM (biological industries) supplemented with 10% heat inactivated fetal bovine serum 
(FBS), 2 mM L-glutamine, 100 units/ml penicillin and 0.1 mg/ml streptomycin. For antibody purification, 293A 
cells were grown in a medium contained equal amounts of RPMI-1640 and DMEM supplemented with 75 units/
ml penicillin, 0.075 mg/ml streptomycin, 2 mM L-glutamine, 1% Nutridoma (Roche) and 1 mM sodium pyruvate 
(biological industries).
Antibody purification. Wild type and mutated antibodies were purified from Hybridoma and 293A super-
natants using protein A or protein G (GE healthcare). Antibodies concentrations were determined by BCA assays 
(Pierce), from 1 L hybridoma culture, ~20 mg mTKH2 antibodies were purified at a concentration of 3 mg/ml. 
From 25 ml culture of 293A cells transfected with hTKH2 plasmids, ~100 µg hTKH2 antibodies were purified at 
a concentration of 1.07 mg/ml.
cDNA synthesis. RNA was extracted from the hybridoma cells BM-4 (ATCC) using TRIzol reagent accord-
ing to the manufacturer instructions (Life) and then reverse transcribed to cDNA by qScript cDNA Synthesis Kit 
according to the manufacturer instructions (Quanta Biosciences).
PCR amplification of anti-AcSTn variable regions. Primers were synthesized according to Tiller et al. 
2009 (IDT Syntezza). First PCR round was performed using Q5 high fidelity DNA polymerase (New England 
BioLabs), with 0.728 ng cDNA in 4 μl as a template (equals to cDNA from 2.4 cells), 300 μM each dNTP, 1.2 U 
Q5 hot start high fidelity DNA polymerase, 200 nM each primer (Supplementary Table 1 primers #1–14) The 
first round was performed at 94 °C for 15 minutes followed by 50 cycles of 94 °C for 30 seconds (s), 55 °C for 
30 s, 72 °C for 55 s and final incubation of 72 °C for 10 minutes. Amplified PCR products were extracted from 
gel using Wizard SV GEL & PCR clean-up system (Promega) according to manufacturer instructions. For VH 
product, a second PCR round was performed. Reaction was made in Q5 reaction buffer, with 2 μl of first PCR 
round product as the template, 300 μM each dNTP, 1.2U Q5 hot start high fidelity DNA polymerase, 200 nM each 
primer (Supplementary Table 3a primers #1 and #15). Reaction conditions of this round were 94 °C for 15 min-
utes followed by 50 cycles of 94 °C for 30 s, 65 °C for 30 s, 72 °C for 45 s and final incubation of 72 °C for 10 min-
utes. Amplified PCR products were extracted from gel. Third PCR round was performed for the amplified VH 
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product. The reaction was carried out in Q5 reaction buffer, with 2 μl of second PCR round product as the tem-
plate, 300 μM each dNTP, 1.2U Q5 hot start high fidelity DNA polymerase, 200 nM each primer (Supplementary 
Table 3a primers #16 and #17). Reaction conditions of this round were 94 °C for 15 minutes followed by 50 cycles 
of 94 °C for 30 s, 62 °C for 30 s, 72 °C for 45 s and final incubation of 72 °C for 10 minutes. Amplified PCR products 
were extracted from gel. The VL PCR product was amplified in a second nested PCR. The reaction was carried 
out in Q5 reaction buffer, with 2 μl of first PCR round result as the template, 300 μM each dNTP, 1.2U Q5 hot start 
high fidelity DNA polymerase, 200 nM each primer (Supplementary Table 3a primers #18 and #19). Reaction 
conditions of this round were 94 °C for 15 minutes followed by 50 cycles of 94 °C for 30 s, 62 °C for 30 s, 72 °C for 
45 s and final incubation of 72 °C for 10 minutes. Amplified PCR products were extracted from gel.
Cloning VH/VL into expression vectors. Purified variable regions were first cloned into pGEM-T easy 
vector (Promega). First, dATPs were added to the insert edges using BIOTAQ DNA Polymerase (bioline) accord-
ing to manufacturer’s instructions. Then, inserts with A-overhang were ligated to pGEM-T easy vector. DH5α 
cells were transformed with pGEM-T easy vector containing anti-AcSTn variable inserts. In order to purify 
the variable inserts, light chain plasmids were digested by AgeI-HF (New England BioLabs), and BsiWI (New 
England BioLabs), heavy chain plasmids were digested by AgeI-HF (New England BioLabs) and SalI-HF (New 
England BioLabs). Digested products were extracted from 1% agarose gel. Human IgG (hIgG) expression vec-
tors (FJ475055, FJ475056) were kindly provided by Prof. Patrick Wilson (University of Chicago). Plasmids for 
heavy and kappa light chain were digested with restriction enzymes (heavy chain expression vector with AgeI-HF 
and SalI-HF, light chain expression vector with AgeIF-HF and BsiWI). Vectors were then treated with Antarctic 
Phosphatase (New England BioLabs) in order to prevent self-closure of the vector. Inserts were ligated with hIgG 
expression vectors using T4 DNA Ligase (New England BioLabs) and plasmids were transformed into DH5α 
cells.
Alanine scanning. Residues were mutated to Alanine by PCR. NEBaseChanger web tool (http://neba-
sechanger.neb.com/) was used to design the primers for the mutagenesis and the primers are shown in 
Supplementary Table 3b. PCR reaction was performed in Q5 reaction buffer (New England Biolabs B9027S) 
supplemented with GC enhancer, with 18 ng plasmid DNA as the template, 200 μM each dNTP, 1U Q5 hot start 
high fidelity DNA polymerase (New England Biolabs M0493L), 500 nM each primer (Supplementary Table 3b), in 
a total volume of 40 μl. The reaction was performed at 98 °C for 30 followed by 25 cycles of 98 °C for 10 s, 58–69 °C 
(depend on the primers Ta) for 20 s, 72 °C for 150 s and final incubation of 72 °C for 2 minutes. PCR products were 
digested with DpnI restriction enzyme (New England BioLabs). The reaction was performed in cut smart buffer, 
with 10 μl of PCR products and 1 μl DpnI enzyme (New England Biolabs) in a total volume of 50 μl. The reaction 
was performed in 37 °C for 8 hours. After digestion, 10 μl of the reaction was transformed into DH5α competent 
cells as described above. Colonies were picked, grown in LB-Amp media overnight, and plasmids were purified 
with NucleoSpin Plasmid EasyPure kit according to manufacturer instructions (Macherey-Nagel) Plasmids were 
sent to sequencing to validate the mutation.
Transfection of 293A cells. 293A cells were grown to 80–90% confluency and evenly spread out across the 
150 mm × 25 mm tissue culture plate. A mixture of 2.4 ml of DMEM and 9 µg of each antibody expression vector 
were prepared. 100 μg of polyethylenimine (PEI; Polysciences) were added to the prepared DMEM and DNA 
mixture that was immediately vortexed, and incubated at RT for 15 minutes. All culture media but 18 ml was 
removed from the plate to be transfected. Then, 2.5 ml of the DMEM, DNA, PEI mixture were supplemented to 
the plate. Subsequent to rocking the plate to ensure even distribution, cells were incubated at 37 °C with 5% CO2 
for 24 hours. Culture media was changed to basal media, 25 ml per plate for incubation of 4 days in 37 °C with 5% 
CO2. Supernatant was collected four days later45.
Sialoglycan microarray fabrication. Arrays were fabricated with NanoPrint LM-60 Microarray Printer 
(Arrayit) on epoxide-derivatized slides (Corning 40044) with 16 sub-array blocks on each slide. Glycoconjugates 
were distributed into one 384-well source plates using 4 replicate wells per sample and 8 µl per well (Version 2.0). 
Each glycoconjugate was prepared at 100 µM in an optimized print buffer (300 mM phosphate buffer, pH 8.4). To 
monitor printing quality, replicate-wells of human IgG (80, 40, 20, 10, 5, 0.25 ng/µl in PBS + 10% glycerol) and 
AlexaFlour-555-Hydraside (Invitrogen A20501MP, at 1 ng/µl in 178 mM phosphate buffer, pH 5.5) were used for 
each printing run. The arrays were printed with four SMP3 pins (5 µm tip, 0.25 µl sample channel, ~100 µm spot 
diameter; Arrayit). Each block (sub-array) has 20 spots/row, 20 columns with spot to spot spacing of 275 µm. 
The humidity level in the arraying chamber was maintained at about 70% during printing. Printed slides were 
left on arrayer deck over-night, allowing humidity to drop to ambient levels (40–45%). Next, slides were packed, 
vacuum-sealed and stored at room temperature (RT) until used.
Sialoglycan microarray binding assay. Slides were developed and analyzed as previously described29 
with some modifications. Slides were rehydrated with dH2O and incubated for 30 min in a staining dish with 
50 °C pre-warmed ethanolamine (0.05 M) in Tris-HCl (0.1 M, pH 9.0) to block the remaining reactive epoxy 
groups on the slide surface, then washed with 50 °C pre-warmed dH2O. Slides were centrifuged at 200 × g for 
three min then fitted with ProPlate™ Multi-Array 16-well slide module (Invitrogen) to divide into the sub-arrays 
(blocks). Slides were washed with PBST (0.1% Tween 20), aspirated and blocked with 200 µl/sub-array of block-
ing buffer (PBS/OVA, 1% w/v ovalbumin, in PBS, pH 7.3) for 1 hour at RT with gentle shaking. Next, the block-
ing solution was aspirated and 100 µl/block of 1:100 diluted sera or purified anti-Neu5Gc antibodies in 10 ng/
µl diluted in PBS/OVA were incubated with gentle shaking for 2 hours at RT. Slides were washed three times 
with PBST, then with PBS for 2 min. Bound antibodies were detected by incubating with secondary detection 
diluted in PBS, 200 µl/block at RT for 1 hour, Cy3-anti Human IgG 1.2 µg/ml (Jackson Immunoresearch). Slides 
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were washed three times with PBST then with PBS for 10 min followed by removal from ProPlate™ Multi-Array 
slide module and immediately dipping in a staining dish with dH2O for 10 min with shaking, then centrifuged at 
200 × g for 3 min. Dry slides immediately scanned.
Array slide processing. Processed slides were scanned and analyzed as described at 10 μm resolution with 
a Genepix 4000B microarray scanner (Molecular Devices) using 300 gain. Image analysis was carried out with 
Genepix Pro 6.0 analysis software (Molecular Devices). Spots were defined as circular features with a variable 
radius as determined by the Genepix scanning software. Local background subtraction was performed.
Array apparent KD calculations. Slides were developed with purified hTKH2 wild-type and mutant anti-
bodies at serial dilutions ranging from 60–3.84 × 10−4 ng/µl (400–0.00256 nM) in blocking buffer (PBS/OVA). 
Apparent KD was calculated according to non-linear fit with one-site specific binding using GraphPad Prism 6.0.
Molecular Modeling. Modeling of TKH2 mAb. VH and VL models were built using either PIGS server 
(http://circe.med.uniroma1.it/pigs) or by the recently developed knowledge-based AbPredict algorithm26. 
AbPredict program models the antibody variable domain by assembling backbone fragments from natural anti-
bodies and recombining them in silico; the sequence of the query antibody is threaded on these backbone models, 
relaxed using Rosetta, and three clustered low-energy conformations are chosen as the predicted structures19.
Modeling of antigen. GLYCAM-Web (www.glycam.org/cb)27 was used to generate 3D models Neu5Acα2–
6GalNAcα-OMe. As the α2–6-sialyl linkage is known to adopt multiple rotamers in solution, it was repre-
sented using six separate 3D structures for each permutation of rotamer combination (ϕ ≈ −60° or 180°, ϕ: 
C1-C2-O6′-C6′, ω ≈ 60°, −60° or 180°, ω: O6-C6-C5-O5).
Molecular Dynamics Simulations of Homology Models. All MD simulations were performed using the Amber14 
software suite. Using tleap46, the 3D structures were placed in a cubic box of TIP5P47 water with a 10 Å water 
buffer with counterions to neutralize the system. The FF14SB48 and Glycam06j28 force fields were employed for 
the protein and the carbohydrate respectively. Protein 1–4 scaling factors were used for the protein portion only. 
Cut-offs of 10.0 Å for vdWs and 8.0 Å for electrostatics were employed. Initial energy minimization (10,000 steps 
steepest decent followed by 10,000 steps conjugate gradient) was performed with Cartesian restraints (5 kcal/mol 
throughout all phases) on all solute heavy atoms to optimize the water molecules position and orientation. The 
same restraints were employed during a 400 ps nPT equilibration phase at 300 °K. This was followed by a 1 ns 
structural equilibration phase with Cartesian restraints on protein Cα. The atom positions and velocities from 
the last step of equilibration were used to start a 100 ns production run, with Cartesian restrains on the Cα atoms 
of the residue in heavy and light chain that connect to the larger Ab structure.
General Docking Protocol. All docking calculations were performed using “Vina-Carb 1.1.2”21, an extension to 
the Autodock Vina program49. The antibody CDR co-ordinates were transformed to the origin and aligned to 
the z-axis and an energy range of 10, with chi values of 1 and 2 were selected as described21. Twenty modes were 
output per docking run.
Rigid ligand docking to a flexible receptor. Twentyfive snapshots were extracted at regular intervals from the MD 
simulation using cpptraj. Each of the six rotamers of Neu5Acα2–6GalNAcα-OMe was docked rigidly to each 
snapshot of the antibody. Four protein residues (Y32.H, R96.H, F97.H and W91.L) whose sidechains were flexible 
in the MD were set as flexible during the docking.
Flexible ligand docking to a rigid receptor. 150 snapshots were extracted at regular intervals from the MD simula-
tion using cpptraj50. The lowest energy rotamer of Neu5Acα2–6GalNAcαOMe, as reported by GLYCAM-Web39, 
was docked with flexible exocyclic bonds to each snapshot of the receptor.
Clustering. For each glycan rotamer, the 500 poses generated by rigid docking were clustered with a 
density-based scan (DBSCAN) in cpptraj program (a program designed to load and analyze molecular dynamics 
trajectories and relevant data sets derived from their analysis; 2 Å cutoff, minpoints = 1 and no sieving). For each 
rotamer, the top scoring pose from the top 20 most populated clusters was subjected to MD simulation (120 poses 
in total).
Post Filtering of Docked Poses using Molecular Dynamics Simulations. The same protocol as for “Molecular 
Dynamics Simulations of Homology Models” was followed, except that the production run was 100 ns.
Rescoring using autodock. Snapshots were extracted at regular from the last 1 ns of the simulation using cpptraj, 
and rescored in place using Vina-Carb.
STD-NMR. A 30 µL, 6.3 mM solution of Neu5Acα2–6GalNAcα1-propylamine in water was lyophilized and 
redissolved in 90 µL D2O to make a 2.1 mM solution of ligand. 30 µL of the stock solution of purified mTKH2 
antibody in water (3.05 µg/µL or approximately 20 µM) was diluted to 90 µL with D2O. Reference 1D proton 
spectra were collected with these samples on an Agilent 600 MHz spectrometer equipped with a 3 mm cryoprobe 
using a standard Agilent ‘dpfgse-water’ pulse sequence for water suppression. The STD sample was prepared 
by mixing 45 µL of the 2.1 mM ligand solution and 45 µL of the 20 µM mAb stock solution to give an approxi-
mate 100:1 molar ratio (10 µM Ab, 1.03 mM ligand). Preliminary data was collected at 600 MHz with the Agilent 
‘dpfgse-satxfer’ pulse program, with irradiation at –1.5 ppm for a range of times. The above STD sample was then 
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lyophilized, redissolved in 99.96% D2O, and used to collect reference proton, and STD data at 900 MHz with 
2 s irradiation time, which was used in the analysis. Data was processed using Mestrenova software (Mestrelab 
Research S.L.) with 1 Hz Gaussian line broadening, zero filling and 3rd order polynomial baseline correction. 
Integral values were obtained by line fitting each multiplet and deconvoluting overlapped peaks when possible. 
Resonance assignments were based on literature values (www.casper.organ.su.se/casper) and confirmed with 
analysis of COSY, TOCSY, HSQC and HMBC data collected at 600 and 900 MHz using standard Agilent pulse 
sequences.
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